Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.70 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.70 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.70 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16942402 | 1.00 | CYP2B6 (0.70) | CYP2B6TENT4ATENT4BMDM2 | |
| SCHEMBL16942403 | 1.00 | CYP2B6 (0.70) | CYP2B6TENT4ATENT4BMDM2 | |
| SCHEMBL16930183 | 0.95 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL16942387 | 0.95 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL16942386 | 0.95 | CYP2B6 (0.63) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21043364 | 0.92 | CYP2B6 (0.73) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20284786 | 0.91 | CYP2B6 (0.61) | CYP2B6TENT4ATENT4BMDM2 | |
| SCHEMBL16980853 | 0.91 | CYP2B6 (0.57) | CYP2B6TENT4ATENT4BMDM2 | |
| SCHEMBL16929875 | 0.90 | CYP2B6 (0.57) | CYP2B6TENT4ATENT4B | |
| SCHEMBL16981155 | 0.90 | CYP2B6 (0.57) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330678-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| EP-3846808-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-07-14 | — | — | EP | claimed |
| WO-2018087345-A1 | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | claimed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | claimed |
| EP-3099685-B1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | claimed |
| WO-2017211791-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND A TLR7 AGONIST | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-14 | — | — | WO | claimed |
| WO-2017114812-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN INTERFERON | F. HOFFMANN-LA ROCHE AG (CH) | 2017-07-06 | — | — | WO | claimed |
| WO-2017108630-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | claimed |
| WO-2017102648-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND A NUCLEOS(T)IDE ANALOGUE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | claimed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | claimed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | claimed |
| US-9458153-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | claimed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | claimed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | claimed |
| EP-3490987-B1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION | GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD (CN) | 2022-09-21 | — | — | EP | disclosed |
| CN-109715624-B | Novel therapeutic agents for the treatment of HBV infection | 广州麓鹏制药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | CYP2B6 30/4885TENT4A 3692/4885TENT4B 2900/4885 |
| US-20210330678-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | CYP2B6 3451/4885TENT4A 154/4885TENT4B 109/4885 |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | CYP2B6 30/4885TENT4A 3692/4885TENT4B 2900/4885 |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, DHX15 | CYP2B6 30/4885TENT4A 3692/4885TENT4B 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.